Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in North America has been steadily growing in recent years due to various factors.
Customer preferences: There has been an increase in demand for immunosuppressants in North America due to the rising prevalence of autoimmune diseases, organ transplants, and cancer. Patients with these conditions require immunosuppressant drugs to help manage their symptoms and improve their quality of life. Additionally, there has been a shift towards the use of biologics, which are more effective and have fewer side effects compared to traditional immunosuppressants.
Trends in the market: The United States is the largest market for immunosuppressants in North America, accounting for the majority of the region's sales. However, Canada and Mexico are also seeing growth in their immunosuppressant markets. The trend towards biologics is expected to continue, with more drugs in this category being approved by regulatory agencies. There is also a growing interest in personalized medicine, which involves tailoring treatment to an individual's specific genetic makeup.
Local special circumstances: The healthcare systems in North America vary by country, which can impact the availability and accessibility of immunosuppressants. In the United States, there is a complex system of insurance coverage and reimbursement that can make it difficult for some patients to afford their medications. In Canada, the government provides universal healthcare coverage, but there are still challenges in accessing certain drugs, particularly in rural areas. In Mexico, there are disparities in healthcare access between urban and rural areas, which can affect the availability of immunosuppressants.
Underlying macroeconomic factors: The North American pharmaceutical market is highly regulated, with strict requirements for drug approval and pricing. The high cost of research and development for new drugs can also impact the pricing of immunosuppressants. Additionally, the aging population in North America is driving demand for healthcare services, including immunosuppressant drugs. The COVID-19 pandemic has also had an impact on the immunosuppressant market, with some patients delaying or avoiding treatment due to concerns about the virus. However, the pandemic has also highlighted the importance of immunosuppressants for patients with autoimmune diseases and organ transplants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
